Blogs

Automated Container Closure Integrity Testing (CCIT) of pre-filled syringes is a critical quality control process that ensures the product inside the syringe remains safe and effective during its shelf life. Pre-filled syringes are used to package and deliver various injectable drugs, such as vaccines, insulin, and other biologics.

The container closure integrity of pre-filled syringes can be compromised due to various factors such as: microcracks, defects in the rubber stopper, or improper sealing. To detect any potential defects in pre-filled syringes, automated CCI testing is done. This testing involves subjecting the pre-filled syringe to multiple conditions to check for any leakage or breakage in the container or closure.

Automated CCI testing of pre-filled syringes can be done utilizing techniques such as vacuum decay, high voltage leak detection, and tracer gas detection. These methods involve the use of specialized equipment to subject the pre-filled syringe to certain conditions including vacuum, high voltage, or exposure to a tracer gas. Any potential leaks or breakages in the container or closure can be detected by monitoring the pressure or electrical conductivity changes, or by the presence of the tracer gas

Automated CCI testing is crucial to ensure the safety and efficacy of pre-filled syringes. It is a reliable and efficient way of detecting potential defects in pre-filled syringes and ensuring that only products which meet the required quality standards are released to the market.

The E-Scan RTX platform is PTI’s fully automated, modular container closure integrity testing solution for pre-filled syringes. The RTX is a practical and reliable CCI solution that features a dynamic robotic design, tailored to fit your production requirements. This robust, adaptable platform utilizes MicroCurrent HVLD technology, a revolutionary form of HVLD that is the ideal CCI solution for high-risk, delicate biologic liquids. It provides a rapid PASS/FAIL result – its test cycle is only seconds – and is suitable for batch release testing, in line on production or in the lab.

PTI’s MicroCurrent HVLD technology uses a unique mode of DC voltage, applying no more than 50% of the voltage used on conventional high-voltage technologies. The nature of the PTI solution allows for the detection of leaks in packages with liquids of extreme low conductivities, including packages containing sterile water. The low voltage and current applied to the container also reduce the voltage the product is exposed to during the test. This technological advantage makes it the ideal solution for all parenteral and biologic solutions.

• MicroCurrent HVLD technology is effective across all parenteral products, including biologics and extremely low conductivity liquids including sterile water (WFI).
• Listed in USP Chapter 1207 as the recommended method for parenteral liquid package inspection.
• Robust method and good Signal-Noise-Ratio between good and defective products.
• Low voltage exposure reduces production of ozone.